Management of Type 2 Diabetes Mellitus and Cardiovascular Risk: Lessons from Intervention Trials

ISSN： 0012-6667

Source： Drugs, Vol.60, Iss.5, 2000-11, pp. : 975-983

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacological Strategies to Reduce Cardiovascular Risk in Type 2 Diabetes Mellitus: An Update

By Marcel M.C. Hovens Jouke T. Tamsma Edith D. Beishuizen Menno V. Huisman

Drugs, Vol. 65, Iss. 4, 2005-01 ,pp. : 433-445

Adis International

Access to resources Recommend Favorite

Future anti-inflammatory metabolic and cardiovascular management of Type 2 diabetes mellitus

By Laight David W

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 11, 2003-11 ,pp. : 1683-1689

Informa Healthcare

Access to resources Recommend Favorite

Sex Differences in Type-2 Diabetes: Implications for Cardiovascular Risk Management

Current Pharmaceutical Design, Vol. 23, Iss. 10, 2017-05 ,pp. : 1471-1476

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus

By Rendell M.

Drugs, Vol. 64, Iss. 12, 2004-01 ,pp. : 1339-1358

Adis International

Access to resources Recommend Favorite

The incretin system in the management of type 2 diabetes mellitus

By Stephens Jeffrey W

Clinical Medicine, Vol. 10, Iss. 5, 2010-10 ,pp. : 491-495

Royal College Of Physicians

Access to resources Recommend Favorite